Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.

Article Authors: L A Morrow, M Leonsson-Zachrisson, H Ericsson, M Wollbratt, M Knutsson, M Hompesch, E Norjavaara

no alt text set

Abstract

To assess the safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus (T2DM).

no